R Nawroth
Overview
Explore the profile of R Nawroth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reike M, Ingersoll M, Muller D, Zuiverloon T, Strandgaard T, Kamat A, et al.
Urol Oncol
. 2022 Oct;
41(5):211-218.
PMID: 36266219
Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line...
2.
Schulz W, Hoffmann M, Niegisch G, Fussel S, Nawroth R
Urologe A
. 2020 Apr;
59(6):731-732.
PMID: 32242269
The annual symposium of the German Research Association for Bladder Carcinoma (DFBK) was organized on February 7th and 8th, 2020, in Düsseldorf. On the first day, eight international guest speakers...
3.
Hofbauer S, Kalogirou C, Roghmann F, Seitz A, Vallo S, Wezel F, et al.
Urologe A
. 2016 Sep;
56(2):202-207.
PMID: 27604705
In January 2015, the research group "bladder cancer research" was founded as part of the GeSRU Academics research initiative. A general challenge to work successfully in a novel network structure...
4.
Fussel S, Kramer M, Stohr R, Olbert P, Nawroth R, Schulz W
Urologe A
. 2016 May;
55(5):663-4.
PMID: 27138635
No abstract available.
5.
Holm P, Retz M, Gschwend J, Nawroth R
Urologe A
. 2015 Nov;
55(3):356-63.
PMID: 26556269
Therapeutic intervention using oncolytic viruses is called virotherapy. This type of virus is defined by the ability to replicate in tumor cells only and to destroy these cells upon replication....
6.
Horn T, Laus J, Seitz A, Maurer T, Schmid S, Wolf P, et al.
World J Urol
. 2015 Jun;
34(2):181-7.
PMID: 26055646
Background: Intratumoural lymphocytic infiltration is strongly associated with the outcome of many human epithelial cancers. The current paper investigated whether subpopulations of tumour-infiltrating T lymphocytes are associated with certain clinicopathological...
7.
Thalgott M, Heck M, Eiber M, Souvatzoglou M, Hatzichristodoulou G, Kehl V, et al.
J Cancer Res Clin Oncol
. 2015 Feb;
141(8):1457-64.
PMID: 25708944
Purpose: Circulating tumor cell (CTC) counts might display a superior prognostic value for overall survival (OS) compared to objective response criteria (OR) in metastatic castration-resistant prostate cancer (mCRPC) patients. Methods:...
8.
Sathe A, Guerth F, Cronauer M, Heck M, Thalgott M, Gschwend J, et al.
Br J Cancer
. 2014 Oct;
111(11):2103-13.
PMID: 25349966
Background: Alterations in the phosphoinositide 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) signalling pathway are frequent in urothelial bladder cancer (BLCA) and thus provide a potential target for novel therapeutic strategies. We...
9.
Nawroth R, Weckermann D, Retz M
Urologe A
. 2014 Mar;
53(4):514-8.
PMID: 24671250
The prognosis of prostate and bladder cancer patients is predominantly determined by the detection of distant sites of metastasis. In clinical routine, virtually only lymph node staging is of relevance...
10.
Heck M, Retz M, Nawroth R
Urologe A
. 2014 Mar;
53(4):484-90.
PMID: 24671247
A positive lymph node status is a major prognostic factor for tumor recurrence and mortality following radical prostatectomy in prostate cancer patients or radical cystectomy in bladder cancer patients. However,...